A Study of TAS-120 in Patients With Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|FGFR 1 High Amplification|FGFR2 Amplification
Interventions: DRUG: Futibatinib|DRUG: Futibatinib plus Fulvestrant
Sponsor: Taiho Oncology, Inc.